Factors associated with the use of cannabis for self-medication by adults: data from the French TEMPO cohort study

Author:

Wallez SolèneORCID,Kousignian Isabelle,Hecker Irwin,Rezag Bara Selma Faten,Andersen Astrid Juhl,Melchior Maria,Cadwallader Jean-Sébastien,Mary-Krause Murielle

Abstract

Abstract Background Medical cannabis, legalized in many countries, remains illegal in France. Despite an experiment in the medical use of cannabis that began in March 2021 in France, little is known about the factors associated with the use of cannabis for self-medication among adults. Methods Data came from the French TEMPO cohort and were collected between December 2020 and May 2021. Overall, 345 participants aged 27–47 were included. Cannabis for self-medication was defined using the following questions: ‘Why do you use cannabis?’ and ‘In what form do you use cannabis?’. The penalized regression method “Elastic net” was used to determine factors associated with the use of cannabis for self-medication, with the hypothesis that it is mainly used for pain in individuals who have already used cannabis. Results More than half of the participants reported having ever used cannabis (58%). Only 10% used it for self-declared medical reasons (n = 36). All self-medication cannabis users, except one, were also using cannabis for recreational purposes. The main factors associated with cannabis use for self-medication vs. other reasons included cannabis use trajectories, the presence of musculoskeletal disorders, tobacco smoking, and parental divorce. Conclusions Engaging in cannabis use during adolescence or early adulthood may increase the likelihood of resorting to self-medication in adulthood. Due to the propensity of individuals with cannabis use during adolescence to resort to uncontrolled products for self-medication, this population should be more systematically targeted and screened for symptoms and comorbidities that may be associated with cannabis use.

Funder

Institut pour la Recherche en Santé Publique

Alliance Nationale pour les Sciences de la Vie et de la Santé

Agence Nationale de la Recherche

Mission Interministérielle de Lutte Contre les Drogues et les Conduites Addictives

Institut National Du Cancer

Pfizer Foundation

IRESP

Publisher

Springer Science and Business Media LLC

Reference67 articles.

1. Abuhasira R, Shbiro L, Landschaft Y. Medical use of cannabis and cannabinoids containing products – Regulations in Europe and North America. Eur J Intern Med. 2018;49:2–6.

2. Achenbach TM. DSM-Oriented Guide for the Achenbach System of Empirically Based Assessment (ASEBA®) An Integrated System of Multi-Informant Assessment; 2015. Available from: https://aseba.org/wp-content/uploads/DSM-Oriented-Guide-for-the-ASEBA.pdf. Cited 2022 Jun 7.

3. Agence Nationale de Sécurité du Médicaments et des produits de santé (ANSM). Cadre et mise en oeuvre de l’expérimentation du cannabis médical [Framework and implementation of medical cannabis experimentation] ; 2021. Available from: https://ansm.sante.fr/dossiers-thematiques/cannabis-a-usage-medical/cadre-et-mise-en-oeuvre-de-lexperimentation-du-cannabis-medical.

4. Aljandaleh H, Bolze C, El-Khoury Lesueur F, Melchior M, Mary-Krause M. Factors Associated with Electronic Cigarette Use among Young Adults: The French “Trajectoires EpidéMiologiques en POpulation” (TEMPO) Cohort Study. Subst Use Misuse. 2020;55(6):964–72.

5. Azcarate PM, Zhang AJ, Keyhani S, Steigerwald S, Ishida JH, Cohen BE. Medical reasons for marijuana use, forms of use, and patient perception of physician attitudes among the US Population. J Gen Intern Med. 2020;35(7):1979–86.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3